Egret Therapeutics

Recent Finacing

Pre-Series A

Recent Raise

Undisclosed

Egret Therapeutics is a New York–based clinical-stage biotherapeutics company developing EGT-101 to treat delayed cerebral ischemia after subarachnoid hemorrhage and advancing a broader neurological disease pipeline.

Founded 2019

New York, United States

1-10

Private

egrettherapeutics.com

Highlights

Focus Areas

Biotechnology

Health Care

Therapeutics

Recent Investors

Financials

1

Funding round

2

Investors

Team

Upgrade to view the team

See the team members at Egret Therapeutics.